Artelo Biosciences Presents Highly Encouraging Data Toward Developing Solid Dosage Form of ART12.11

Artelo Biosciences, Inc. recently announced Dr. Andrew Yates presented new preclinical data on ART12.11 at the CT-CANN24 conference held May 29-30, 2024, at the Hilton London Canary Wharf in London, UK.

The presentation, titled An Aqueous Suspension of a Novel Cannabidiol: Tetramethylpyrazine Co-crystal, demonstrates a pharmacokinetic profile comparable with Epidiolex® in Rats, highlights the company’s patented cocrystal of CBD and TMP (tetramethylpyrazine), ART12.11, in an unoptimized formulation, demonstrated comparable pharmacokinetics of CBD and its metabolites to a mimic of Epidiolex, an FDA approved oral solution of CBD in ethanol and sesame oil used for controlling seizures in orphan childhood disorders with over $845 million in net sales for 2023. Oral solutions are commonly used for treating young children; however, for adolescents and adults a solid dosage form is preferred. A tablet form of ART12.11 is expected to be more attractive than an oral solution given its advantages in precise dosing, storage and transport.

Andrew Yates, PhD, Chief Scientific Officer and Senior Vice President of Artelo, said “We are excited to present our first comparative data of ART12.11 versus an Epidiolex-like formulation of CBD to the cannabinoid research community. The data not only shows we can outperform an equivalent formulation of CBD but also that ART12.11 already has comparable CBD levels in plasma provided by Epidiolex. The data we have from both the rat and dog pharmacokinetic studies provide us confidence that we can design an optimized solid-dosage form for the clinic, that will open new frontiers for CBD clinical research in broader populations.”

As previously reported, ART12.11 offers improvements in physicochemical, pharmacokinetics, and pharmacodynamic properties compared to CBD. In addition, strong evidence previously announced with ART12.11 in an animal study of stress-induced anxiety and depression showed Artelo’s cocrystal composition outperformed CBD with just a third of the amount of CBD in the cocrystal than in the comparator arm of CBD alone. This data highlights Artelo’s opportunity to reduce the expected pill burden with its oral solid formulation and the company is currently developing an optimized tablet of ART12.11 for planned clinical studies.

ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Superior pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The US issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. For more information, visit www.artelobio.com.